Fiskus, W
Sharma, S
Saha, S
Shah, B
Devaraj, S G T
Sun, B
Horrigan, S
Leveque, C
Zu, Y
Iyer, S
Bhalla, K N
Article History
Received: 9 July 2014
Revised: 10 October 2014
Accepted: 16 October 2014
First Online: 8 December 2014
Competing interests
: Stephan Horrigan is Chief Scientific Officer of β-Cat Pharma, Inc. The remaining authors declare no conflict of interest.